Where does Genovus Biotechnologies Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Genovus Biotechnologies Inc. ranks #47,018 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Genovus Biotechnologies Inc. hold?

Genovus Biotechnologies Inc. holds 5 US utility patents granted between 2019 and 2023, spanning 4 technology areas.

What is Genovus Biotechnologies Inc.'s Innovation Score?

Genovus Biotechnologies Inc. has an Innovation Score of 35.3 out of 100 (top 50% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Genovus Biotechnologies Inc. focus on?

Genovus Biotechnologies Inc.'s top technology area is A61B (DIAGNOSIS; SURGERY; Identification) with 5 patents, ranking #3,118 of 7,127 assignees active in that subclass. Grants appear in 4 CPC subclasses total.

Is Genovus Biotechnologies Inc.'s patent grant rate increasing or decreasing?

Genovus Biotechnologies Inc.'s recent grant velocity is +300% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Genovus Biotechnologies Inc.'s patents?

Genovus Biotechnologies Inc.'s patents average 20.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Genovus Biotechnologies Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Genovus Biotechnologies Inc.

USPTO PatentsView assignee record - 5 granted patents across 4 technology areas, recorded in grant years 2019–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Genovus ranks #47,018 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 4 technology areas.

#47,018
of 49,997 US assignees by volume: Top 50%
by Innovation Score (35.3/100): 20.0
avg claims per patent: +300%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R47018 · US Corporation #47,018 · 5 grants

GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 5 grants
BOTTOM-DECILE #47,018/49,997
PHOTO-FINISH Genesis Biologics…
CPC-NARROW A61B · 4 areas
INNOV-THIN 35.3/100
CLAIMS-DENSE 20.0 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +300% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Genesis Biologics Holdings Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Genovus’s 35.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 6.2 pts (18%) Velocity 10.0 pts (28%) Breadth 7.1 pts (20%) Claim depth 12.0 pts (34%)

Qualcomm Incorporated · highest

85
Blackbird · near

35
Cree Fayetteville · near

35
Genovus Biotechnolog… · this assignee

35
Rockwell · near

35
WINBO-Dongjian… · near

35
3D Lighting… · lowest

7

What this shows Genovus's Innovation Score is 35.3/100 (top 50% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Genovus?

Each dot is one of Genovus’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Genovus’s own 20.0 claims/patent is ABOVE the 15.6 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Genovus vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Genovus's grants concentrate

Genovus Biotechnologies Inc. is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). Peak complete grant year is 2023 (2 grants) versus a trough of 1 in 2019. By volume, Genovus sits between Genesis Biologics Holdings Ltd. and Geotech Corp.

Genovus's three-year grant acceleration

Genovus Biotechnologies Inc. shows 3 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Genesis Biologics…

5
Genesis Filters

5
Geneticure

5
Genius Toy Taiwan

5
Geosea

5
Georg Schlegel &…

5
Georgy Viktorovic…

5
Geotech

5
Genovus Biotechno… ◀

5

What this shows Genovus holds 5 patents at rank #47,162, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Genovus

By rank, the assignees closest to #47,162 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in Genovus's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Genovus, neither rank-band nor same-CPC leaders (those blocks stay above). In A61B (Diagnosis), Genovus ranks #3,118 of 7,127 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (35 here).

Rockwell LLC 35 Blackbird PLC 35 Cree Fayetteville, Inc. 35 WINBO-Dongjian Automotive Technology Co., Ltd. 35

Genovus's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

35 Top 50% higher than 50% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2019–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table

Genovus Biotechnologies Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2019	1	20.0%
2021	1	20.0%
2022	1	20.0%
2023	2	40.0%

Which technologies does Genovus Biotechnologies Inc. patent most?

A61B - DIAGNOSIS; SURGERY; Identification 5

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 5

A61H - Physical Therapy Apparatus, e.g. Devices FOR Locating OR Stimulating Reflex Points IN THE BODY; Artificial RESPIRATION; MASSAGE; Bathing Devices FOR Special Therapeutic OR Hygienic Purposes OR Specific Parts OF THE Body 3

H05H - Plasma Technique ; Production OF Accelerated Electrically-charged Particles OR OF NEUTRONS; Production OR Acceleration OF Neutral Molecular OR Atomic Beams 2

Top 4 of 4 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Genovus Biotechnologies Inc.'s patent record in context - here's where to go next.

Genovus Biotechnologies Inc.'s lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 100% of its portfolio - see every assignee active in that class. Explore A61B
Ranked #47,018 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Genovus Biotechnologies Inc. against Genesis Biologics Holdings Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 35.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.